Title : Transforming immune therapy: A reverse pathway in B-lymphocytes for super-antibody technology to cure infectious diseases and cancer

Abstract:

Until today, the contemporary Adaptive Immunology is using Clonal Selection Theory (CST) as a main Theory of Adaptive Immunology for explanation of how Adaptive Immune system is working in mammals.

But after 5 years (2010-2015) of my theoretical research results did show that CST is totally wrong.

I have theoretically discovered 2 novel main mechanisms which will change whole Molecular Adaptive Immunology Conception and Theories and will bring very powerful novel Super-Antibody Technology for curing of all of Infectious Diseases and Cancer!  My novel Discoveries are:

1. (First Discovery) All of Naïve B-cells (NBCs) which are produced in Bone Marrow have the same structure!  There is not Random Rearrangements as CST is alleging! All of the NBC’s have on membrane surfaces the same IgM and IgD, which are not affine to any Antigen Epitope (AE)!  They are using as a Receptors for interaction with Dendritic Cells (DC) for getting one of the Intraluminal Vesicles (ILV) with Antigen Epitopes (AE) on MHC-2 from Multi-vesicular Body (MVB) of DC!
   
   Th cells do not have this mechanism! Th cell activation and production of massive Th-cell Cytokines depends quantities (at least 50-to 100) of AE’s on MHC-2) which NBC has got from DC! Th cell connected with small amount of AE’s on DC can’t be activated by DC! Th cells just docking on the DC, but not being activated!
    
2. (Second Discovery) After interaction and activation Th cell by NBC, Th cell is producing massive amount of Cytokines, which are bringing reciprocal activation of NBC. Under Th Cytokines, NBC produces unknown yet enzyme which connects Anti-Codon triplets of t-RNAs with activated amino-acids (aa) which are non-covalently connected with affine  aa of AE and that way creates short endosomal RNA (e-RNA) in the endosome of NBC!  Then with the help of Nuclear Receptor(s) this nascent e-RNA relocates to VDJ section of Heavy Chain (HC) and replace Replicable Module (p-N-D-N-p) of HC DNA and only after that V part of HC is coding affine aa-s to giving AE!  I have call this mechanism Reverse Pathway mechanism, which explain why IgG is the first and abundant (75% of all Ig-s in the blood) and affine Ig-s in the body!
   
   My novel Conception and Reverse Pathway Theory scientifically explain all of real processes which are happening in Molecular Adaptive Immunology! Contemporary CST is wrong and have to be replaced with my novel Conception and Reverse Pathway Theory, which will bring a novel and very powerful Super-Antibody Technology for curing of all of Infectious Diseases and Cancer.

Biography:

Victor Alexander was born in 1952 in the Genge Region of the Azerbaijan Republic, located in the Southern Caucasus. He graduated from high school with a Gold Medal and went on to complete his medical education at the State Medical University, earning his MD diploma in 1976. He worked as a medical doctor at State Hospital #1 for three years. Have got PhD in Medicine degree and Diploma in 1984 and worked as an assistant of Professor in the Pharmacology Department and continued my Research project in embryonic, pre- and post-natal development area! Two times he was the winner of All-Union Competition of young Pharmacologists of USSR in Moscow, in 1973 and 1975. After eruption of long war between Azerbaijan and Armenia, he immigrated to USA, CA and became CA, USA citizen (2001) as an advanced PhD degree Research Scientist. From 2006 to 2008, he trained in stem cell research at UC Davis. Since 2009, he has been actively engaged in research as the President and Principal Investigator of his private stem cell research company based in Sacramento, California. Victor Alexander has made significant contributions to theoretical adaptive immunology and is the author and originator of the novel Reverse Pathway Theory and Super-Antibody (SAb) Technology. His groundbreaking work has been recognized with Certificates of Recognition from two international congresses: The World Congress on Molecular Immunology and Immunogenetics in London (2018) and the World Congress on Biotechnology in Philadelphia (2019).